Menu
/REGISTER
PPB
Montecito
ROAM
Loading...
You are here:  Home  >  Health Care  >  Current Article

Amgen updates agreement with DaVita for dialysis treatment

By   /   Monday, January 9th, 2017  /   Comments Off on Amgen updates agreement with DaVita for dialysis treatment

    Print       Email

Thousand Oaks biotech company Amgen entered into a six-year supply agreement with DaVita for dialysis treatments, the company announced on Jan. 9.

Under the terms of the new agreement, Amgen will supply DaVita with Epogen and Aranesp for agents to stimulate red blood cells in dialysis treatment in the United States and Puerto Rico. The new agreement, which offers discount pricing and rebates, will replace the Nov. 15, 2011 agreement that would have expired on Dec. 31, 2018.

Amgen shares went up 1.3 percent to $158.84 on Jan. 9.

• Contact Alex Kacik at [email protected]

 

 

    Print       Email

You might also like...

Chiquita renews banana shipping contract with Port of Hueneme

Read More →